Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($1.32), $0.07 worse than the analyst estimate of ($1.25).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge